Skip to main content
Premium Trial:

Request an Annual Quote

Affy Posts 12-Percent Rise in Q3 Revenue as Loss Swings to Profit

NEW YORK (GenomeWeb News) — Affymetrix late yesterday said that third-quarter revenue rose 12 percent as R&D spending declined 24 percent and last year’s loss swung to a profit.

Total revenue for the three months ended Sept. 30 increased to $95 million from $84.7 million year over year.

For the quarter, Affy said product sales increased about 23 percent to $69.4 million; product-related revenue slipped 12 percent to $15.8 million; royalties and other revenue rose about 58 percent to $9.5 million; and revenue from Perlegen Sciences dropped to $355,000 from $4.6 million.

The company said GeneChip consumable revenue was $65.4 million, consisting of array revenue of $42.9 million, reagent revenue of $15.8 million, and genotyping services revenue of $6.3 million. Instrument revenue was $10.7 million for the quarter.

R&D spending fell to $16.5 million from $21.6 million in the prior-year period. The company posted a $2.6 million profit from a loss of $14.2 million year over year.

Affy had $250.7 million in cash, equivalents, and short-term investments as of Sept. 30.

The company said it expects total 2007 revenue in the range of $365 million to $375 million.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.